Description
What is CJC-1295 No DAC & Ipamorelin?
The CJC-1295 No DAC & Ipamorelin dual reference complex (commonly designated as CJC 1295 ipamorelin, CJC-1295/ipamorelin, CJC/IPA, or IPA/CJC) is a precision-formulated peptide combination engineered to investigate dual-receptor somatotropic axis activation. The combination pairs CJC-1295 No DAC(also known as Modified GRF 1-29), a 29-amino-acid synthetic analogue of endogenous Growth Hormone Releasing Hormone (GHRH), with Ipamorelin, a selective pentapeptide growth hormone secretagogue.
When evaluated independently, each peptide targets a distinct, complementary receptor class on pituitary somatotropes. When studied in combination, the CJC 1295 peptide complex produces a pronounced synergistic response, elevating growth hormone synthesis and secretion significantly beyond the calculated additive output of either compound alone, while maintaining complete receptor selectivity.
Batch-verified for high analytical purity at Chicago BioResearch Labs, the CJC-1295 No DAC & Ipamorelin blend is offered in two standardized laboratory formats:
- 5MG/5MG dual lyophilized reference powder vial complex
- 10MG/10MG dual lyophilized reference powder vial complex
Laboratories researching pituitary secretagogue kinetics, intracellular signal amplification, and neuro-endocrine feedback loops evaluate this blend alongside complementary secretagogues available on the site, such as Tesamorelin, Sermorelin, GHRP-2, and GHRP-6.
Chemical and Molecular Data
| Compound Complex | CJC-1295 No DAC (Modified GRF 1-29) + Ipamorelin Blend |
|---|---|
| Quantity / Formats Offered | 5MG/5MG Lyophilized Powder Vials |
| CJC-1295 No DAC Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Ipamorelin Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Numbers | 863288-34-0 (CJC-1295 No DAC) | 170851-70-4 (Ipamorelin) |
| Chemical Formulas | C152H252N44O42 (CJC-1295) | C38H49N9O5 (Ipamorelin) |
| Molecular Weights | 3367.20 g/mol (CJC-1295 No DAC) | 711.86 g/mol (Ipamorelin) |
| IUPAC Name (CJC-1295 No DAC) | Modified Growth Hormone Releasing Factor (1-29) amide |
| InChIKey (Ipamorelin) | InChIKey=HUPFGBLSBRKMLB-UHFFFAOYSA-N |
What are the Mechanisms of Action?
The biochemical pathways and cellular targets of the CJC-1295 ipamorelin complex in laboratory research include:
- GHRH Receptor Activation (Gs-cAMP Pathway): CJC-1295 No DAC selectively binds the Growth Hormone Releasing Hormone (GHRH) receptor on somatotrope cell membranes. Receptor occupancy activates stimulatory G-protein (Gs), triggering adenylate cyclase to convert ATP into cyclic AMP (cAMP). Elevated intracellular cAMP activates Protein Kinase A (PKA), upregulating growth hormone gene transcription and priming secretory vesicles.
- GHS-R1a Activation (Gq/11-Ca2+ Pathway): Ipamorelin binds the Growth Hormone Secretagogue Receptor (GHS-R1a / Ghrelin receptor) with high nanomolar affinity. This activates the Gq/11 protein subunit, stimulating Phospholipase C (PLC) to cleave membrane lipids into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers rapid calcium (Ca2+) release from the endoplasmic reticulum into the cytosol.
- Dual-Receptor Somatotrope Synergy: Simultaneous activation of the Gs/cAMP cascade (CJC-1295) and the Gq/11/Ca2+ cascade (Ipamorelin) creates intracellular signal amplification. The concurrent rise in PKA phosphorylation and cytosolic Ca2+ drives exocytosis of primed GH storage granules, resulting in a robust, natural pulsatile secretion pattern.
What do Preclinical & Academic Studies Show for CJC-1295 & Ipamorelin?
When evaluating research efficacy and published scientific literature for CJC 1295 ipamorelin reference materials:
- Somatotrope Secretagogue Selectivity (PubMed): Landmark pharmacological studies cataloged on PubMed (PMID: 9839330) demonstrate that Ipamorelin stimulates growth hormone release with extreme selectivity, displaying zero affinity for ACTH, cortisol, prolactin, or aldosterone receptors in pituitaries.
- GHRH Receptor Kinetics & Peptide Stability (PMC): Comprehensive biomedical reviews archived in PMC (PMC8540866) confirm that tetrasubstitution in Modified GRF 1-29 (CJC-1295 No DAC) prevents rapid dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage, maintaining high biological potency in somatotrope cell models.
- Chemical Profiling & Identification (PubChem): Official structural characterization maintained on PubChem verifies the molecular mass, amino acid sequences, and mass spectrometry profiles of CAS 863288-34-0 (CJC-1295) and CAS 170851-70-4 (Ipamorelin).
How does the CJC/IPA blend compare to individual peptides?
To evaluate receptor crosstalk, signal transduction kinetics, and secretagogue potency, researchers compare the CJC-1295 No DAC & Ipamorelin complex against standalone reference peptides available at Chicago BioResearch Labs:
| Compound / Reference | Primary Receptor Target | Core Mechanism of Action | Research Focus & Profile |
|---|---|---|---|
| CJC-1295 No DAC & Ipamorelin Blend | Dual GHRH Receptor & GHS-R1a Agonist | Simultaneously activates Gs/cAMP and Gq/11/Ca2+pathways, producing synergistic GH pulse amplification | Focuses on dual-pathway somatotrope synergy, physiological GH pulse modeling, and maximal secretagogue receptor cross-talk |
| CJC-1295 No DAC (Mod GRF 1-29) | GHRH Receptor (Gs-Coupled) | Stimulates adenylate cyclase to elevate cAMP and PKA, priming GH gene transcription and vesicle synthesis | Focuses on isolated GHRH receptor kinetics, enzymatic resistance against DPP-IV, and baseline GH transcription research |
| Ipamorelin | GHS-R1a Ghrelin Receptor (Gq/11-Coupled) | Triggers Phospholipase C (PLC) to mobilize cytosolic Ca2+, driving exocytosis of stored GH granules | Focuses on highly selective ghrelin receptor agonism without off-target cortisol, ACTH, or prolactin elevation |
| Tesamorelin | N-Terminal Trans-3-Hexenooyl GHRH Analogue | Binds GHRH receptors with high stability, modulating hepatic IGF-1 transcription and lipid metabolism | Focuses on high-affinity GHRH receptor signaling, hepatic gene expression, and visceral lipid metabolic modeling |
Reviews
There are no reviews yet.